E
EGRX

Ergoteles’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ergoteles’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-69,275
Closed -$1.35M – 917
2023
Q2 		$1.35M Buy
69,275
+26,598
+62% +$631K 0.06% 372
2023
Q1 		$1.21M Buy
42,677
+31,107
+269% +$923K 0.05% 428
2022
Q4 		$338K Buy
+11,570
New +$368K 0.01% 869
2022
Q3 		– Sell
-45,636
Closed -$2.03M – 2094
2022
Q2 		$2.03M Buy
45,636
+22,118
+94% +$1.02M 0.06% 315
2022
Q1 		$1.16M Buy
+23,518
New +$1.13M 0.04% 387
2021
Q1 		– Sell
-7,100
Closed -$331K – 1122
2020
Q4 		$331K Buy
+7,100
New +$332K 0.01% 517

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's EGRX Position: Q3 2023 in Review

Ergoteles sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 69,275 shares — an estimated $1.35M sold.

Ergoteles first reported a position in EGRX in Q4 2020 and held it in 6 quarters. The position peaked at $2.03M in Q2 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Ergoteles reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 69,275 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.35M.
  • Ergoteles first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 6 quarters.
  • Ergoteles's Eagle Pharmaceuticals, Inc. position peaked at $2.03M in Q2 2022.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.